New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors

January 29, 2024

https://www.globenewswire.com/news-release/2024/01/29/2818910/0/en/New-Company-Eyconis-Formed-to-Develop-Ascendis-Pharma-Ophthalmology-Assets-with-150-Million-Commitment-from-External-Investors.html

COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq:ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital.

Read more at globenewswire.com

Related news for (ASND)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.